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Abstract
Background: Current chemotherapy of human African trypanosomiasis or sleeping sickness relies
on drugs developed decades ago, some of which show toxic side effects. One promising line of
research towards the development of novel anti-trypanosomal drugs are small-molecule inhibitors
of Trypanosoma brucei cysteine proteinases.
Results: In this study, we demonstrate that treatment of T. brucei-infected mice with the inhibitor,
carbobenzoxy-phenylalanyl-alanine-diazomethyl ketone (Z-Phe-Ala-CHN2), alters parasite
morphology and inhibits cell division. Following daily intra-peritoneal administration of 250 mg kg-
1 of Z-Phe-Ala-CHN2 on days three and four post infection (p.i.), stumpy-like forms with enlarged
lysosomes were evident by day five p.i. In addition, trypanosomes exposed to the inhibitor had a
65% greater protein content than those from control mice. Also, in contrast to the normal 16% of
parasites containing two kinetoplasts – a hallmark of active mitosis, only 4% of trypanosomes
exposed to the inhibitor were actively dividing, indicating cell cycle-arrest.
Conclusion: We suggest that inhibition of endogenous cysteine proteinases by Z-Phe-Ala-CHN2
depletes the parasite of essential nutrients necessary for DNA synthesis, which in turn, prevents
progression of the cell cycle. This arrest then triggers differentiation of the long-slender into short-
stumpy forms.
Background
Trypanosoma brucei is the aetiological agent of human Afri-
can trypanosomaisis or sleeping sickness. At present there
are only four drugs available for treatment of sleeping
sickness and some of these induce serious side effects [1].
With this in mind, recent research has shown that small-
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molecule inhibitors of Clan CA cysteine proteinases [2,3]
kill T. brucei in vitro and alleviate parasitiemia in mouse
models of the disease [4-7]. As possible targets for these
inhibitors, two cysteine proteinases have been identified.
The first, an ortholog of mammalian cathepsin B (tbcatB),
is a single copy gene and expressed in both procyclic and
bloodstream forms, but with greater detectable mRNA
levels in the latter stage [8]. As yet, its sub-cellular locali-
zation is unclear but may be in either the endosome and/
or lysosome. Tetracycline-induced RNAi of tbcatB resulted
in dysmorphic parasites leading to cell death [8], raising
the possibility that tbcatB may be a useful molecular target
for disease intervention.
The second potential target for cysteine proteinase inhibi-
tors, termed trypanopain-Tb [5], brucipain [6] or rhode-
sain [9], is a cathepsin L-like cysteine proteinase [10,11]
encoded by 11 gene copies [12] and predominant in
terms of enzymatic activity [9]. Inhibition of brucipain by
the small molecule inhibitor, carbobenzoxy-phenylala-
nyl-alanine-diazomethyl ketone (Z-Phe-Ala-CHN2), cor-
related with the compound's trypanocidal action in vivo
[4]. Also, this and other peptidyl inhibitors blocked pro-
teinolysis in the lysosome as evidenced by the accumula-
tion of undigested FITC-transferrin [4,7], data consistent
with the lysosomal localization of brucipain using specific
antibodies [9,13]. Brucipain is developmentally
expressed, with approximately five-fold more protein
found in short-stumpy forms than in either long-slender
or procyclic forms [9].
Here, we demonstrate that Z-Phe-Ala-CHN2 when admin-
istered to mice infected with T. brucei results in parasites
with altered cell morphology, a decreased capacity to
degrade intracellular protein and an inability to mitoti-
cally replicate. We discuss these findings with respect to
the parasite proteases targeted by Z-Phe-Ala-CHN2.
Results
To study the effect of Z-Phe-Ala-CHN2 on the cell mor-
phology and cell division activity of bloodstream-form
trypanosomes in vivo, mice infected with T. brucei were
injected i.p. once daily on days 3 and 4 p.i. with 250 mg
kg-1 of the inhibitor or vehicle alone. On day 5 p.i., blood
smears were prepared and parasites were isolated from
infected blood.
For examining the cell morphology of the parasites by
light microscopy, blood smears were stained with May-
Grünwald dye. In the blood of control mice, a mixed pop-
ulation of dividing long-slender forms and cell-arrested
short-stumpy forms was found (Fig. 1b), with signifi-
cantly (four times) more long-slender forms. In contrast,
the blood of Z-Phe-Ala-CHN2-treated mice contained few
long-slender forms and almost all trypanosomes (>90%)
appeared as stumpy-like forms (Fig. 1a). In addition, a
large blue-stained region was observed between the kine-
toplast and the nucleus, i.e., in a position consistent with
that of the lysosome (Fig. 1a). That this is the lysosome is
corroborated by the fact that the May-Grünwald dye stains
acidic cell components. Long-slender and short-stumpy
forms from control mice did not contain this structure
(Fig. 1b).
Upon electron microscopy, trypanosomes from Z-Phe-
Ala-CHN2-treated mice were considerably larger than
those from control mice (Fig. 2). Also, the lysosomes of
trypanosomes exposed to the inhibitor were significantly
larger than those of short-stumpy forms from control
mice (Fig. 2). The enlargement of the lysosome may also
explain why this organelle could be easily observed by
light microscopy after May-Grünwald staining. In addi-
tion, the mitochondrion were also enlarged (Fig. 2).
Next, the protein content of trypanosomes purified from
Z-Phe-Ala-CHN2-treated and control mice was compared.
Trypanosomes exposed to the inhibitor had 65% more
Effect of Z-Phe-Ala-CHN2 on the morphology of T. brucei  bloodstream forms in vivo Figure 1
Effect of Z-Phe-Ala-CHN2 on the morphology of T. 
brucei bloodstream forms in vivo. Mice that had been 
infected with the pleomorphic variant clone AnTat 1.1 were 
injected intraperitoneally with 250 mg kg-1 of Z-Phe-Ala-
CHN2 or vehicle alone on days 3 and 4 p.i. On day 5 p.i., 
blood smears were prepared and stained with May-Grün-
wald's stain solution. Representative examples from Z-Phe-
Ala-CHN2-treated mice (a) and control mice (b) are shown. 
Trypanosomes exposed to the inhibitor appeared stumpy-
like with a blue-stained region (arrowhead) between the 
kinetoplast and the nucleus, a location that is consistent with 
that of the lysosome in bloodstream forms. k, kinetoplast; n, 
nucleus; LS, long-slender forms; SS, short-stumpy forms.Kinetoplastid Biology and Disease 2007, 6:2 http://www.kinetoplastids.com/content/6/1/2
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protein than parasites from untreated animals; the mean
values were 8.9 and 5.4 pg cell-1, respectively (Table 1).
Thus, the microscopically observed enlargement of
trypanosomes exposed to Z-Phe-Ala-CHN2  correlated
with a higher protein content of the cells.
To determine the number of dividing cells, blood smears
were stained with the DNA-binding fluorochrome DAPI
and examined by fluorescence microscopy. Trypano-
somes were considered to be dividing if the parasites con-
tained two kinetoplasts. In contrast to the 16% of the
normal trypanosome population containing two kineto-
plasts, just 4% of parasites exposed to Z-Phe-Ala-CHN2
were dividing (Table 2). As the segregation of the kineto-
plast precedes trypanosomal cytokinesis [14], this result
indicates that the cell division of trypanosomes was
impaired under the influence of Z-Phe-Ala-CHN2.
Effect of Z-Phe-Ala-CHN2 on the size of the lysosome of T. brucei bloodstream forms in vivo Figure 2
Effect of Z-Phe-Ala-CHN2 on the size of the lysosome of T. brucei bloodstream forms in vivo. Mice were infected 
and treated as described in the legend to Fig. 1. On day 5 p.i., trypanosomes were purified and processed for electron micros-
copy. Ultrathin sections of representative cells purified from mice treated with Z-Phe-Ala-CHN2 (a) and vehicle alone (b) are 
shown. Note the enlarged lysosome in the trypanosome exposed to Z-Phe-Ala-CHN2 compared with that in the short-stumpy 
form from control mice. fl, flagellum; fp, flagellar pocket; ly, lysosome, m, mitochondrion. Bar, 0.5 μm.
Table 1: Protein content of T. brucei bloodstream forms purified from Z-Phe-Ala-CHN2-treated and control mice.
Protein content (pg cell-1)
Z-Phe-Ala-CHN2-exposed trypanosomes Control trypanosomes
Experiment 1 9.1 6.5
Experiment 2 8.7 4.2
Average 8.9 5.4Kinetoplastid Biology and Disease 2007, 6:2 http://www.kinetoplastids.com/content/6/1/2
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Discussion
Previously, we demonstrated that small molecule inhibi-
tors of cysteine proteinases kill T. brucei in culture and
experimentally-infected mice [4,6]. We now report that
upon treatment of infected mice with the diazomethyl
ketone inhibitor, Z-Phe-Ala-CHN2, parasite death is pre-
ceded by an increase in cell body mass and enlargement
of constituent organelles (lysosome and mitochondrion)
with a predominance (>90%) of trypanosomes displaying
a "stumpy-like" morphology. Swelling of the cell body
prior to cell lysis has been reported previously for blood-
stream forms of T. brucei and T. cruzi after incubation with
peptidyl fluoromethyl ketones in vitro [15]. The mecha-
nism proposed involved inhibition of cysteine proteinase
activity.
Treatment with Z-Phe-Ala-CHN2  elicited a striking
enlargement of the lysosome of trypanosomes coincident
with the appearance of the same organelle after staining
with May-Grünwald's solution. This suggests that the
inhibitor prevents normal proteolysis in the lysosome
thereby allowing the accumulation of undegraded pro-
teins and the consequent increase in parasite weight
(Table 1). The alteration in lysosomal size and function is
consistent with the previous finding that co-incubation of
cultured  T. brucei bloodstream forms with Z-Phe-Ala-
CHN2 and FITC-labelled transferrin prevented degrada-
tion of the latter in the lysosome [4]. However, the lack of
increased electron density in the enlarged lysosome, as
would normally be expected upon accumulation of unde-
graded proteins, may suggest an increased water permea-
bility of the organelle.
While it is formally possible that Z-Phe-Ala-CHN2 exerts
its trypanocidal action through one or more off-target
mechanisms, one likely molecular target responsible for
the enlarged lysosome phenotype is brucipain given that
it is localized in the lysosome [9] and that exposure to the
inhibitor in vivo results in a marked decrease (92%) in cel-
lular cysteine protease activity, most of which is due to
brucipain [4]. It is also possible that the phenotype was a
result of inhibition of tbcatb by Z-Phe-Ala-CHN2, even
though a sub-cellular localization of this enzyme consist-
ent with the phenotype is as yet unknown [8]. Interest-
ingly, tetracycline-induced RNAi of tbcatB, but not
brucipain, induced a lethal phenotype prefaced by an
enlarged endosome/lysosome compartment [8] similar to
that consequent on exposure to Z-Phe-Ala-CHN2. The
conclusions were that tbcatb, not brucipain, was essential
to T. brucei survival and that tbcatb was the most likely tar-
get of the inhibitor [8]. However, with respect to bruci-
pain, both of these judgments are open to reinterpretation
given the available data. First, fully 35% of rhodesain
activity remained in the presence of tetracycline-induced
RNAi [8], possibly sufficient to allow for normal cell func-
tion and the lack of an obvious phenotype. Therefore, it is
still unclear what a total knock-down of brucipain might
yield in terms of the parasite's ability to survive. Secondly,
Z-Phe-Ala-CHN2 is chemically reactive with both mam-
malian cathepsins B and L [16,17] and there is no quanti-
tative data to suggest that tbcatb is preferentially inhibited
by this compound. Indeed, it has been shown that, in T.
brucei lysates, both brucipain and a 34 kDa proteinase spe-
cies (consistent with the molecular weight of tbcatb) are
inhibited by Z-Phe-Ala-CHN2 [9].
For other protozoan parasites, morphological aberrations,
consistent with the prevention of normal proteinolysis,
have been noted upon application of cysteine proteinase
inhibitors. Thus, incubation of T. cruzi epimastigotes with
the cysteine proteinase inhibitor morpholinourea-pheny-
lalany-homophenylalanine vinylsulfone phenyl
(K11777) led to enlarged intracellular organelles (endo-
plasmatic reticulum, nuclear membrane, mitochondrion)
and morphological alterations of the Golgi complex [18].
Likewise, for Plasmodium falciparum trophozoites, cysteine
proteinase inhibitors disrupted the morphology of the
food vacuole and prevented degradation of haemoglobin
[19,20].
In addition to the morphological changes, the "stumpy-
like" nature of trypanosomes exposed to Z-Phe-Ala-CHN2
was substantiated by the low number of dividing para-
sites. Only 4% of the parasites were proliferating which is
close to the number of dividing cells (long-slender forms)
of about 2% found in natural short-stumpy enriched pop-
Table 2: Number of T. brucei bloodstream forms purified from Z-Phe-Ala-CHN2-treated and control mice with two kinetoplasts.
Two kinetoplast configuration (%) *
Z-Phe-Ala-CHN2-exposed trypanosomes Control trypanosomes
Experiment 1 3.4 14.9
Experiment 2 4.8 16.4
Average 4.1 15.7
* Analysis of DAPI stained trypanosomes.Kinetoplastid Biology and Disease 2007, 6:2 http://www.kinetoplastids.com/content/6/1/2
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ulations in vivo [21]. Because we observed no increase in
multinucleated cells with aberrant kinetoplast/nucleus
configurations, as can occur under non-physiological con-
ditions [22,23], the low number of dividing cells indicates
Z-Phe-Ala-CHN2 induces a cell cycle arrest.
Transformation of long-slender forms into "stumpy-like"
forms has been previously observed upon treatment with
the methylating agent 1,2-bis(methylsulfonyl)-1-methyl-
hydrazine and the ornithine decarboxylase inhibitor DL-
α-difluoromethylornithine (DFMO) [22,24,25]. Whereas
the primary effect of DFMO is depletion of the intracellu-
lar polyamine pool, that of 1,2-bis(methylsulfonyl)-1-
methylhydrazine is modification of DNA. However, the
subsequent effect of both agents is an inhibition of DNA
synthesis which in turn leads to arrest of the cell cycle
[22,25]. A similar mechanism may also account for the
cell cycle arrest in trypanosomes exposed to Z-Phe-Ala-
CHN2: inhibition of lysosomal proteolysis depletes the
parasite of nutrients necessary for DNA synthesis and this
is followed by blockage of mitosis. The cell-cycle arrest
may also explain why Z-Phe-Ala-CHN2-exposed trypano-
somes are 65% larger than control parasites as they con-
tinue to grow but have stopped dividing.
Conclusion
This study has shown that treatment of T. brucei-infected
mice with the cysteine proteinase inhibitor Z-Phe-Ala-
CHN2  results in an increased number of mitotically-
arrested, stumpy form-like parasites. The findings agree
with previous suggestions that enforced cell cycle arrest
can trigger slender-to-stumpy differentiation [21].
Materials and methods
Reagents
Z-Phe-Ala-CHN2 was purchased from Bachem, Heidel-
berg, Germany; May-Grünwald's stain solution was
obtained from Merck, Darmstadt, Germany; 4,6-diamid-
ino-2-phenylinodole (DAPI) was bought from Sigma,
Deisenhofen, Germany; BCA Protein Assay was from
Pierce Chemical Company (Rockford, IL, USA).
Treatment of T. brucei-infected mice with Z-Phe-Ala-
CHN2
Female BALB/c mice (about 10 weeks old) were infected
intraperitoneally (i.p.) with 2 × 104 cells of the pleomor-
phic T. brucei variant clone AnTat 1.1 [26]. On days 3 and
4 post infection (p.i.) mice were treated once daily with
i.p. injections of 250 mg kg-1 of Z-Phe-Ala-CHN2 dissolved
in 70% DMSO/30% physiological NaCl solution.
Infected control mice received only the vehicle. On day 5
p.i., blood smears were prepared or parasites were purified
from blood by DEAE-cellulose chromatography [27].
Staining of blood smears
Blood smears were stained with May-Grünwald's stain
solution and additionally treated with 0.0001% DAPI to
label the nucleus and the kinetoplast. The stained slides
were examined under a microscope (Axioplan) using a
100X Plan-Neofluar objective in transmitted and fluores-
cence light.
Electron microscopy
Purified trypanosomes were fixed in 2% formaldehyde/
0.05% glutaraldehyde in PBS for 60 min. After embedding
in 1% agarose, cells were post-fixed with 1% osmium
tetraoxide/0.9% ferricyanide in PBS for 60 min followed
by 1% uranyl acetate for 60 min. Cells were dehydrated in
ethanol and subsequently embedded in epoxy resin.
Ultrathin sections were stained with uranyl acetate and
lead citrate, and examined with a Philips 201 electron
microscope at 60 kV.
Protein assay
The protein content of trypanosomes was determined
using the bicinchoninic acid (BCA) method. Lysed
trypanosomes (2.5 – 3.7 × 105 cells in 10 μl) were incu-
bated with 200 μl of BCA Protein Assay reagent at 37°C.
A series of dilutions of BSA (0.1 – 0.9 mg ml-1) was used
to generate a standard curve and each dilution was set up
in duplicate. After 30 min of incubation, the absorbance
at 500 nm was determined using a Dynatech MR5000
ELISA reader.
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